Nintedanib esylate
|
|
|
- CAS-Nr.
- 656247-18-6
- Englisch Name:
- Nintedanib esylate
- Synonyma:
- Nintedanib esylate;Nintedanib ethanesulfonate;Nintedani;NSC 116056;BIBF-1120 esylate;BIBF 1120 esylate;Nintedanib
(Ofev);BIBF 1120 BIBF-1120;Trinidad Neeb esylate;Intedanib ethanesulfonate
- CBNumber:
- CB02509952
- Summenformel:
- C33H39N5O7S
- Molgewicht:
- 649.76
- MOL-Datei:
- 656247-18-6.mol
|
Nintedanib esylate Eigenschaften
- Schmelzpunkt:
- >233°C (dec.)
- storage temp.
- -20°C Freezer
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Yellow solid.
- Farbe
- Light Yellow to Yellow
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Nintedanib esylate Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Nintedanib esylate is a potent, oral triple angiokinase inhibitor
developed by Boehringer Ingelheim that targets proangiogenic and
pro-fibrotic pathways mediated by the vascular endothelial growth
factor receptor, fibroblast growth factor receptor and plateletderived
growth factor receptor families, as well as Src and Flt-3
kinases. It was approved for the treatment of idiopathic pulmonary
fibrosis (IPF), a condition in which the lungs become progressively
scarred over time, by the US FDA in October 2014 and by
the EMA in January 2015. The FDA granted nintedanib esylate
fast-track, priority review, orphan product, and breakthrough
designations. The drug was also approved by the EMA in November
2014 for treatment of non-small cell lung cancer in combination
with docetaxel after first-line chemotherapy.
Verwenden
Nintedanib Esylate is the salt form of Nintedanib, which is angiokinase inhibitor and is used in the treatment of idiopathic pulmonary fibrosis. Also inhibits the process blood vessel formation which may be used to assist in cancer therapy.
Definition
ChEBI: An organosulfonate salt obtained by combining nintedanib with one molar equivalent of ethanesulfonic acid. A kinase inhibitor used for the treatment of idiopathic pulmonary fibrosis and cancer.
Properties and Applications
Nintedanib esylate (NE) is used in the treatment of idiopathic pulmonary fibrosis (IPF) and in diverse cancers, including nonsmall cell lung cancer (NSCLC). NE has a pH-dependent solubility profile with low aqueous solubility under neutral pH and increased solubility at acidic pH. The oral bioavailability of NE is 4.7% because it is a P-gp substrate and also undergoes first-pass metabolism in the liver by esterases. However, the administration of NE along with food increases the area under the curve (AUC) and maximum concentration (Cmax) when the drug is taken with food; hence, it has a positive food effect[1].
Nintedanib esylate Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Nintedanib esylate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 310)Lieferanten
656247-18-6()Verwandte Suche:
- (3Z)-2,3-Dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid methyl ester ethanesulfonate
- BIBF 1120 esylate
- BIBF-1120 esylate
- BIBF1120/nintedanib ethanesulfonate salt
- Trinidad Neeb esylate
- Intedanib ethanesulfonate
- Nintedanib ethanesulfonate salt
- Trinidad Neeb ethanesulfonate
- Nintedanib(ethanesulfonic acid)
- BIBF1120 ethanesulfonate salt
- (Z)-Methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene
- 1H-Indole-6-carboxylic acid,2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]-phenylmethylene]-2-oxo-, methylester, (3Z)-, ethanesulfonate (1:1)
- 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)-, ethanesulfonate (1:1)
- Nintedanib
(Ofev)
- (Z)-methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate ethanesulfonate
- BIBF 1120 BIBF-1120
- BIBF1120; BIBF 1120 BIBF-1120; NINTEDANIB ESYLATE. NINTEDANIB ETHANESULFONATE SALT; INTEDANIB; BRAND NAME OFEV. VARGATEF.
- Brand name OFEV. Vargatef.
- Nintedanib esylate. Nintedanib ethanesulfonate salt
- Nintedanib Ethanesulfonate (Intedanib Ethanesulfonate)
- Nintedani
- NSC 116056
- Nintedanib ethanesulfonate
- Nintedanib esylate
- 6-Benzofuranpropanenitrile,β-oxo-
- methyl (Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate ethanesulfonate
- Buprenorphine Impurity 24
- 656247-18-6
- 1217052-38-5
- C31H33N5O4C2H6O3S
- C33H39N5O7S
- API
